Cancer Research and Treatment

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Xuesong Yang, Yan Wu, Anqiang Wang, Xiuli Ma, Kai Zhou, Ke Ji, Xin Ji, Ji Zhang, Xiaojiang Wu, ZhongWu Li, Zhaode Bu

The Journal of Pathology: Clinical Research.2024;[Epub] CrossRef

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma

Patricia L. Theard, Amanda J. Linke, Nancy E. Sealover, Brianna R. Daley, Johnny Yang, Katherine Cox, Robert L. Kortum

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, Golgodu Krishnamurthy Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, Kaviyarasi Renu, Saikat Dewanjee, Rupa Sanyal, Abhijit Dey, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Val

Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences

Yuhao Ye, Zhiyu Huang, Maoqing Zhang, Jiayue Li, Yiqiong Zhang, Chenghua Lou

Biomedicine & Pharmacotherapy.2023; 159: 114183. CrossRef

Quinolines: Privileged Scaffolds for Developing New Anti‐neurodegenerative Agents

M.Sc.Shivani Chauhan, Tarana Umar, Manpreet K. Aulakh

A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells

Zhilan Zhou, Ya Wang, Zhengtao Shao, Guixi Zhang, Hang Jiang, Yiyuan Tang, Zening Huang, Yingdi Zhu, Juan Li

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy

Journal of Medicinal Chemistry.2023; 66(12): 7670. CrossRef

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

Hugo Arasanz, Luisa Chocarro, Leticia Fernández-Rubio, Ester Blanco, Ana Bocanegra, Miriam Echaide, Ibone Labiano, Ana Elsa Huerta, Maria Alsina, Ruth Vera, David Escors, Grazyna Kochan

International Journal of Molecular Sciences.2023; 24(12): 9855. CrossRef

An Observatory for the MET Oncogene: A Guide for Targeted Therapies

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Zhen-Xi Niu, Ya-Tao Wang, Nan Lu, Jin-Feng Sun, Peng Nie, Piet Herdewijn

European Journal of Medicinal Chemistry.2023; 261: 115868. CrossRef

Shahin Ramazi, Maedeh Dadzadi, Zahra Sahafnejad, Abdollah Allahverdi

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, Jacob M. Hughes, Zaria M. Beckley, Dianna H. Huisman, Deepan Chatterjee, Nancy E. Sealover, Katherine Cox, James W. Askew, Robert A. Svoboda, Kurt W. Fisher, Robert E. Lewis, Robert L. Kortum

Proceedings of the National Academy of Sciences.2023;[Epub] CrossRef

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Pérez, Christian Rolfo, Andrés F. Cardona

Therapeutic Advances in Respiratory Disease.2022; 16: 175346662110660. CrossRef

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

Daniel Lu, Amy Nagelberg, Justine LM Chow, Yankuan T Chen, Quentin Michalchuk, Romel Somwar, William W. Lockwood

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers

Ilaria Martinelli, Chiara Modica, Cristina Chiriaco, Cristina Basilico, James M. Hughes, Simona Corso, Silvia Giordano, Paolo M. Comoglio, Elisa Vigna

Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef

PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Aryana R. Rasti, Amy Guimaraes-Young, Farrah Datko, Virginia F. Borges, Dara L. Aisner, Elena Shagisultanova

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies

Solange Rivas, Arnaldo Marín, Suraj Samtani, Evelin González-Feliú, Ricardo Armisén

International Journal of Molecular Sciences.2022; 23(22): 13898. CrossRef

Advances in the Lung Cancer Immunotherapy Approaches

Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi, Jintae Lee, Raja Ganesan

A comprehensive review on the biological interest of quinoline and its derivatives

Basavarajaiah Suliphuldevara Matada, Raviraj Pattanashettar, Nagesh Gunavanthrao Yernale

Bioorganic & Medicinal Chemistry.2021; 32: 115973. CrossRef

Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer

Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi

Critical Reviews in Oncology/Hematology.2021; 160: 103234. CrossRef

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

Aaron Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel SW Tan

Lung Cancer: Targets and Therapy.2021; Volume 12: 11. CrossRef

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors

Qing Tang, Alex M. Aronov, David D. Deininger, Simon Giroux, David J. Lauffer, Pan Li, Jianglin Liang, Kira McGinty, Steven Ronkin, Rebecca Swett, Nathan Waal, Diane Boucher, Pamella J. Ford, Cameron S. Moody

ACS Medicinal Chemistry Letters.2021; 12(6): 955. CrossRef

Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies

American Society of Clinical Oncology Educational Book.2021; (41): e286. CrossRef

Response to crizotinib in a patient with MET‐amplified hepatocellular carcinoma

Qinglian Chen, Chunfeng Xie, Kunliang Feng, Haijun Huang, Chengming Xiong, Tengjiao Lin, Wenjing Wang, Mian Xu, Xianwei Yang, Chong Zhong

New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications

Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza

Bioorganic & Medicinal Chemistry.2021; 46: 116340. CrossRef

Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer

Alex Martinez-Marti, Enriqueta Felip, Francesco Mattia Mancuso, Ginevra Caratú, Judit Matito, Paolo Nuciforo, Irene Sansano, Nely Diaz-Mejia, Susana Cedrés, Ana Callejo, Patricia Iranzo, Nuria Pardo, Josep Maria Miquel, Alejandro Navarro, Ana Vivancos, Mi

British Journal of Cancer.2021; 125(11): 1561. CrossRef

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Re

Molecular Cancer Therapeutics.2021; 20(10): 1966. CrossRef

Development and full validation of an LC–MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats

Xiaoguang Fan, Guanghu Yang, Wenjuan Cui, Qin Liu, Zhaolong Zhang, Zhikun Zhang

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaro

Journal of Thoracic Oncology.2020; 15(1): 80. CrossRef

Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer

Surgical Pathology Clinics.2020; 13(1): 17. CrossRef

Meta-analysis of functional expression and mutational analysis of c-Met in various cancers

Murugesan Sivakumar, Murugesan Jayakumar, Palaniappan Seedevi, Palaniappan Sivasankar, Muthu Ravikumar, Sundharaiyya Surendar, Tamilselvi Murugan, Shahid S. Siddiqui, Sivakumar Loganathan

Current Problems in Cancer.2020; 44(4): 100515. CrossRef

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Xing Huang, Enliang Li, Hang Shen, Xun Wang, Tianyu Tang, Xiaozhen Zhang, Jian Xu, Zengwei Tang, Chengxiang Guo, Xueli Bai, Tingbo Liang

Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef

Statins use and its impact in EGFR‐TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan

Phung‐Anh Nguyen, Chih‐Cheng Chang, Cooper J. Galvin, Yao‐Chin Wang, Soo Yeon An, Chih‐Wei Huang, Yu‐Hsiang Wang, Min‐Huei Hsu, Yu‐Chuan (Jack) Li, Hsuan‐Chia Yang

A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells

Emerging therapies for non-small cell lung cancer

Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong

Journal of Hematology & Oncology.2019;[Epub] CrossRef

Capmatinib for the treatment of non-small cell lung cancer

Johan Filip Vansteenkiste, Charlotte Van De Kerkhove, Els Wauters, Pierre Van Mol

Expert Review of Anticancer Therapy.2019; 19(8): 659. CrossRef

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement

Ji-Hyun Kwon, Kui-Jin Kim, Ji Hea Sung, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Soyeon Kim, Sung-Soo Yoon, Jong Seok Lee

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291

Yang‐ling Li, Ke Ding, Xiu Hu, Lin‐wen Wu, Dong‐mei Zhou, Ming‐jun Rao, Neng‐ming Lin, Chong Zhang

Journal of Cellular and Molecular Medicine.2019; 23(11): 7427. CrossRef

MiR-1246 Promotes Metastasis and Invasion of A549 cells by Targeting GSK-3β‒Mediated Wnt/β-Catenin Pathway

Fan Yang, Hairong Xiong, Li Duan, Qian Li, Xin Li, Yongqin Zhou

Cancer Research and Treatment.2019; 51(4): 1420. CrossRef